Prevalence of Potentially Severe Drug-Drug Interactions in Ambulatory Patients with Dyslipidaemia Receiving HMG-CoA Reductase Inhibitor Therapy

Author： Bravo Alexandra E. Rätz  

Publisher： Adis International

ISSN： 0114-5916

Source： Drug Safety, Vol.28, Iss.3, 2005-01, pp. : 263-275

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors

By Williams D.   Feely J.  

Clinical Pharmacokinetics, Vol. 41, Iss. 5, 2002-01 ,pp. : 343-370

Adis International

Access to resources Recommend Favorite

Pluripotential Mechanisms of Cardioprotection with HMG-CoA Reductase Inhibitor Therapy

By Rosenson R.S.  

American Journal of Cardiovascular Drugs, Vol. 1, Iss. 6, 2001-06 ,pp. : 411-420

Adis International

Access to resources Recommend Favorite

Age-Related Differences in the Prevalence of Potential Drug-Drug Interactions in Ambulatory Dyslipidaemic Patients Treated with Statins

By Egger Sabin S.  

Drugs & Aging, Vol. 24, Iss. 5, 2007-01 ,pp. : 429-440

Adis International

Access to resources Recommend Favorite

HMG CoA reductase inhibitor [statin] therapy should be considered for older patients

By  

Inpharma, Vol. 1, Iss. 1237, 2000-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Oxidation Injury in Patients Receiving HMG-CoA Reductase Inhibitors: Occurrence in Patients Without Enzyme Elevation or Myopathy

By Sinzinger H.  

Drug Safety, Vol. 25, Iss. 12, 2002-01 ,pp. : 877-883

Adis International

Access to resources Recommend Favorite